Stock Track | Eli Lilly Soars 5.06% Intraday on Positive EU Regulatory Opinion for Leukemia Drug Jaypirca

Stock Track06-26 21:55

Eli Lilly's stock surged 5.06% during intraday trading on Friday, driven by significant positive regulatory news for its drug candidate.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Jaypirca (pirtobrutinib) for approval in the European Union. The recommendation is for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and is based on positive results from two Phase 3 clinical trials that met their primary endpoints.

The application has now been referred to the European Commission, with a final marketing authorization decision expected within the next one to two months. Eli Lilly has also submitted the trial results to the U.S. Food and Drug Administration for approval, with a decision anticipated in the second half of this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189216537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189216537","market":"hk","top_or_hot":-1,"title":"Stock Track | Eli Lilly Soars 5.06% Intraday on Positive EU Regulatory Opinion for Leukemia Drug Jaypirca","media":"Stock Track","content":"<p>Eli Lilly's stock surged 5.06% during intraday trading on Friday, driven by significant positive regulatory news for its drug candidate.</p><p>The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Jaypirca (pirtobrutinib) for approval in the European Union. The recommendation is for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and is based on positive results from two Phase 3 clinical trials that met their primary endpoints.</p><p>The application has now been referred to the European Commission, with a final marketing authorization decision expected within the next one to two months. Eli Lilly has also submitted the trial results to the U.S. Food and Drug Administration for approval, with a decision anticipated in the second half of this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Soars 5.06% Intraday on Positive EU Regulatory Opinion for Leukemia Drug Jaypirca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Soars 5.06% Intraday on Positive EU Regulatory Opinion for Leukemia Drug Jaypirca\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-26 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly's stock surged 5.06% during intraday trading on Friday, driven by significant positive regulatory news for its drug candidate.</p><p>The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Jaypirca (pirtobrutinib) for approval in the European Union. The recommendation is for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and is based on positive results from two Phase 3 clinical trials that met their primary endpoints.</p><p>The application has now been referred to the European Commission, with a final marketing authorization decision expected within the next one to two months. Eli Lilly has also submitted the trial results to the U.S. Food and Drug Administration for approval, with a decision anticipated in the second half of this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1189216537","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189216537","pubTimestamp":1782482127,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly's stock surged 5.06% during intraday trading on Friday, driven by significant positive regulatory news for its drug candidate.The European Medicines Agency's Committee for Medicinal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"个股追踪|欧盟对白血病药物Jaypirca正面监管意见礼来盘中大涨5.06%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly's stock surged 5.06% during intraday trading on Friday, driven by significant positive regulatory news for its drug candidate.The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Jaypirca (pirtobrutinib) for approval in the European Union. The recommendation is for the treatment of adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and is based on positive results from two Phase 3 clinical trials that met their primary endpoints.The application has now been referred to the European Commission, with a final marketing authorization decision expected within the next one to two months. Eli Lilly has also submitted the trial results to the U.S. Food and Drug Administration for approval, with a decision anticipated in the second half of this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189216537","isCrawlerRequest":true}